My Pitch Was Interrupted by the CEO's Daughter Saying, "We Don't Need Your Ideas Anymore"

Solar Therapeutics

At 3:00 p.m. exactly, my phone rang.

“Hello, Kieran,” I answered. “Have you decided if you’re interested in seeing something that actually works?”.

“I’m listening,” he replied. “But I’m not alone”.

“Who’s with you?”.

“The entire investment group. After this morning’s situation, we need certainty”.

I smiled to myself.

“Text me the address. I’ll bring everything you need to see”.

Two hours later, I stood before six of the industry’s most powerful investors in a private conference room at their downtown offices. No Ellis, no Belle, just me and the work I dedicated years to perfecting.

“Before I begin,” I said, setting up my equipment, “I want to be clear about something: what you’re about to see belongs to me, not to Ellis’s company”.

Kieran leaned forward.

“That contradicts what we were told yesterday”.

“I imagine many things you were told yesterday won’t hold up to scrutiny”.

I launched into my presentation, explaining the true methodology behind the stabilization process. I demonstrated the results with samples I’d prepared, allowing them to verify the efficacy themselves.

When I finished, the room was silent for several seconds. Finally, Kieran spoke.

“This is remarkable work, Veta, but it raises serious questions about what happened at Ellis’s company”.

“I can answer those questions,” I said, “but first I need to know if you’re interested in funding the actual innovation, not just a presentation about it”.

Another investor, Amara, spoke up.

“Are you saying you’ve established your own company?”.

“I have, as of 3 weeks ago”.

Kieran’s eyebrows rose.

“3 weeks before yesterday’s presentation”.

I nodded.

“I sensed which way the wind was blowing. And the process? The intellectual property belongs to me personally, developed through independent research conducted outside company hours using my own resources”.

“Ellis will fight that claim,” Amara said.

“Let him try,” I replied, sliding a folder across the table. “This contains documentation of every step I took to protect my work, verified by independent legal counsel”.

Kieran opened the folder, scanning its contents with growing interest.

“You’ve been planning this for months”.

“I’ve been protecting myself for months,” I corrected. “There’s a difference”.

“And what exactly happened this morning?” Amara asked. “Why couldn’t their lab replicate the results?”.

I met her gaze steadily.

“Because they never fully understood the process to begin with. They had my results but not my methodology. Belle saw the destination but not the path”.

“That’s devastating for them,” Kieran said slowly.

“Yes,” I agreed. “It is”.

The investors exchanged glances, a silent conversation happening above the polished conference table. I remained standing, calm despite the butterflies in my stomach. This moment would determine everything.

“We need to discuss this privately,” Kieran finally said.

I nodded, gathering my materials.

“Of course”.

“No,” Amara interrupted, raising her hand. “Stay, please. I have more questions”.

I paused, caught between the impulse to give them space and the need to maintain momentum.

“Your documentation shows you developed this innovation independently,” she continued, tapping the folder, “but you were employed by Ellis during this time. Most contracts have clauses about intellectual property”.

“Mine did as well,” I acknowledged. “Which is why I was careful to develop the critical components on my own time, with my own equipment”.

“The lab results they have show a version that works, but not the refined process I’ve developed since realizing what was happening”.

“And when was that exactly?” another investor asked.

“When Belle arrived,” I said simply. “She asked too many specific questions, spent too much time examining my notes rather than understanding the science”.

“After the second time I caught her going through my desk after hours, I created a separate research path”.

Kieran’s eyebrows shot up.

“You have proof of that?”.

I nodded.

“Security footage. I requested it claiming I’d misplaced some notes. The cameras caught her at my workstation at 10:30 p.m. on three separate occasions when I wasn’t present”.

The room went quiet again. I could see the calculations happening behind their eyes, not just financial ones, but reputational. Nobody wanted to back a company built on stolen research.

“What exactly are you proposing?” Kieran finally asked.

“My company, Solar Therapeutics, is seeking investment to bring this stabilization process to market”. “We’re small but focused: no bloated management structure, no nepotism, just scientists who understand what we’re building”.

“And your team is currently?”.

“Four people, including myself, all experts who left Ellis’s company in the past year due to,” I paused, choosing my words carefully, “leadership concerns”.

Amara nodded slowly.

“You’ve been planning your exit strategy for some time”.

“I’ve been protecting my work,” I corrected again. “The exit became necessary when it became clear my contributions wouldn’t be respected or acknowledged”.

One of the quieter investors leaned forward.

“What makes your process different from what we saw yesterday? In layman’s terms”.

I appreciated the question. This was my element: the science itself, not the politics around it.

“Imagine trying to deliver medicine to a specific part of the body. Traditional methods are like throwing darts blindfolded: some might hit the target, but most scatter elsewhere, causing side effects”. “My process creates what you might call a guided missile system. The medication remains stable until it reaches exactly where it’s needed, then activates precisely”.

“And the applications?”.

“Cancer treatment initially, delivering chemotherapy directly to tumors without damaging surrounding tissue”. “Eventually, the platform could work for neurological conditions, autoimmune disorders—anywhere we need targeted treatment”.

The energy in the room shifted. This wasn’t just about corporate drama anymore; it was about potential that transcended it.

“We need to verify your claims independently,” Kieran said, his voice carrying new respect.

“I welcome that,” I replied.

“In the meantime,” Amara added, “I suggest we pause our discussions with Ellis’s company”.

The meeting concluded with handshakes and promises of follow-up discussions. As I packed my presentation materials, Kieran approached me privately.

“Ellis called me six times today,” he said quietly.

I continued organizing my papers.

“That’s unfortunate”.

“He claims you stole research”.

“That would be projection on his part”.

Kieran studied me for a moment.

“You knew this would happen, all of it”.